Literature DB >> 12391389

Insulin glargine: a new basal insulin analogue.

N Younis1, H Soran, D Bowen-Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391389     DOI: 10.1093/qjmed/95.11.757

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


× No keyword cloud information.
  5 in total

Review 1.  Evolving approaches to intensive insulin therapy in type 1 diabetes: multiple daily injections, insulin pumps and new methods of monitoring.

Authors:  Elizabeth Stephens; Matthew Riddle
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 6.514

2.  Recombinant A22(G)-B31 (R)-human insulin. A22 addition introduces conformational mobility in B chain C-terminus.

Authors:  Piotr Borowicz; Elżbieta Bednarek; Wojciech Bocian; Jerzy Sitkowski; Beata Jaworska; Jerzy Mikołajczyk; Tadeusz Głąbski; Dorota Stadnik; Weronika Surmacz; Monika Bogiel; Lech Kozerski
Journal:  J Biomol NMR       Date:  2012-02-14       Impact factor: 2.835

3.  Insight into human insulin aggregation revisited using NMR derived translational diffusion parameters.

Authors:  Jerzy Sitkowski; Wojciech Bocian; Elżbieta Bednarek; Mateusz Urbańczyk; Wiktor Koźmiński; Piotr Borowicz; Grażyna Płucienniczak; Natalia Łukasiewicz; Iwona Sokołowska; Lech Kozerski
Journal:  J Biomol NMR       Date:  2018-06-12       Impact factor: 2.835

4.  Systemically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes.

Authors:  Jiaxu Li; Yang Kuang
Journal:  Math Biosci Eng       Date:  2009-01       Impact factor: 2.080

5.  Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease.

Authors:  Jiling Li; Zhengping Feng; Qifu Li; Yan He; Changhong Zhao; Jun He
Journal:  Exp Ther Med       Date:  2014-04-24       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.